Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis

Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis

Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades. It becomes the preferred treatment choice after patients have failed conventional chemotherapy. We conducted a meta-analysis in 320 patients from 14...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Therapeutics and clinical risk management 2019-05, Vol.15, p.637-646
Hauptverfasser: Drokow, Emmanuel Kwateng, Ahmed, Hafiz Abdul Waqas, Amponsem-Boateng, Cecilia, Akpabla, Gloria Selorm, Song, Juanjuan, Shi, Mingyue, Sun, Kai
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Autologous
Cancer
Cancer treatment
CAR-T
Care and treatment
CD19
Chemotherapy
haematological malignancies
Immunotherapy
Inflammation
Medical research
Original Research
Patient outcomes
Prognosis
Response rate
T cells
Tocilizumab
Toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Chimeric Antigen Receptor T(CAR-T) cell therapy is an immunotherapy approach used in treating cancer which has seen rapid development over the decades. It becomes the preferred treatment choice after patients have failed conventional chemotherapy. We conducted a meta-analysis in 320 patients from 14 studies to estimate the survival outcome, response rate and toxicity of autologous CD19 CAR-T cell therapy and predict other factors associated with a better prognosis. The overall response rate was 71.88% (95% CI: 61.34-80.46%,
ISSN:1176-6336
1178-203X
1178-203X
DOI:10.2147/TCRM.S203822